The 2023 MIT Asia Roadshow in Osaka presents an opportunity to learn about various MIT-connected startups across diverse industries, including Artificial Intelligence, Energy, Life Sciences, Robotics, Sustainability, and Proptech.
The agenda for the day includes a series of insightful lightning talks, exhibitions showcasing the work of innovative startups, and networking sessions with professionals from MIT-connected startups, as well as the larger industry.
The 2023 MIT Asia Roadshow in Seoul presents an opportunity to learn about various MIT-connected startups across diverse industries, including Artificial Intelligence, Energy, Life Sciences, Robotics, Sustainability, and Proptech.
The 2023 MIT Asia Roadshow in Tokyo presents an opportunity to learn about various MIT-connected startups across diverse industries, including Artificial Intelligence, Energy, Life Sciences, Robotics, Sustainability, and Proptech.
Proctor & Gamble is seeking a technology solution to manage the e2e Creative Content Supply chain.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.
Scalable production of RNA for agriculture Andrey Zarur, Cofounder & CEO, GreenLight Biosciences Potassium fertilizer innovation Philip Wender, Managing Director, Advanced Potash Technologies Chemiresistive gas sensing for food safety Merry Smith, Senior Scientist, C2Sense Novel dehumidifying material for indoor farms Sorin Grama, Cofounder, Transaera Probiotics for plants Michael Miille, CEO, Joyn Bio [Joyn is a JV between Ginkgo Bioworks and Leaps by Bayer]
Christina Qi, Partner, Domeyard LP
Panel moderator: Marcus Dahllof, Program Director, MIT Startup Exchange Panelists: Caleb Harper, Director, OpenAg, MIT Media Lab Dilip Sundaram, President, Corporate, Mahindra Group - Americas Jan Schnorr, CEO, C2Sense Alan Kriz, Strategic Alliance Manager, Crop Science, Bayer Tejal Mody, Managing Director, Rabobank